- What: U.S. District Judge Yvonne Gonzalez Rogers ruled that Elon Musk’s ketamine use is off-limits for OpenAI’s legal team.
- When: The ruling precedes a jury trial scheduled to begin on April 27.
- Financial Stakes: Musk is suing over a $38 million donation; OpenAI is currently valued at approximately $500 billion.
- Core Dispute: Musk alleges OpenAI committed fraud by abandoning its non-profit mission for a commercial partnership with Microsoft.
A federal judge has blocked OpenAI and CEO Sam Altman from probing Elon Musk’s use of ketamine during the discovery phase of an upcoming fraud trial. The ruling by U.S. District Judge Yvonne Gonzalez Rogers ensures that the billionaire’s personal medical habits will not be used to undermine his allegations that the generative AI giant defrauded him by pivoting from a non-profit research lab to a profit-driven enterprise.
The decision arrives as both parties prepare for an April 27 jury trial in Oakland, California. The case centers on Musk’s claim that OpenAI—a company he helped co-found in 2015 with a $38 million investment—breached its founding agreement by prioritizing commercial interests and its multibillion-dollar partnership with Microsoft over the benefit of humanity.
A "Testy" Road to Trial
The ruling follows a series of aggressive legal maneuvers from both sides. OpenAI’s attorneys previously requested a judgment against Musk, contending he lacked a factual basis for his fraud and breach of contract claims. However, Judge Gonzalez Rogers emphatically rejected the motion to dismiss during a recent 90-minute hearing.
"This case is going to trial," Gonzalez Rogers stated, according to reports from the hearing. The judge noted that while some evidence may be circumstantial, it is sufficient for a jury to decide whether OpenAI "hoodwinked" its co-founder during its evolution.
By barring the ketamine probe, the court has narrowed the legal theater to the technical and financial transition of the company, rather than the personal conduct of its high-profile plaintiff. OpenAI had reportedly sought to explore Musk's drug use, which has been a topic of public discussion, potentially as a means to challenge his recollection of early agreements or his standing as a victim of fraud.
From Non-Profit Roots to a $500 Billion Valuation
The trial will dissect the historical trajectory of OpenAI, which launched in 2015 as a non-profit research lab. Musk alleges that he was induced to provide millions in funding under the premise that the organization would develop artificial general intelligence (AGI) for the public good and keep its technology open-source.
Musk left the company in 2018 following disagreements over control and direction. Since his departure, OpenAI has restructured into a "capped-profit" entity, secured a massive investment from Microsoft, and released industry-defining products like ChatGPT. This transition has propelled OpenAI's valuation to a staggering $500 billion, a figure that Musk's legal team points to as evidence of the company’s "capitalistic" shift.
"Elon Musk donated $38 million to OpenAI when it promised to remain nonprofit," according to court filings. The billionaire entrepreneur now claims the company’s evolution into a Microsoft-backed powerhouse constitutes a "betrayal" of its original charter.
Impact on AI Governance and Corporate Law
The outcome of this trial could set a massive precedent for the AI industry, specifically regarding the enforceability of "mission-driven" founding documents. If Musk succeeds, it may force other AI startups to reconsider how they balance ethical research goals with the immense capital requirements of modern model training.
For developers and the broader industry, the trial represents a public audit of AI's power structures. The "shareable angle" here is the shift in power: the man who helped build the most valuable AI company in the world is now its most dangerous legal adversary.
"This case represents a fundamental question for the industry: Can an AI company's soul be sold to the highest bidder once the technology becomes profitable?"
The ruling to exclude Musk’s ketamine use suggests the court is interested in the merits of the corporate contract rather than character assassination. By keeping the focus on the $38 million donation and the $500 billion valuation, the judge is forcing OpenAI to defend its business model rather than attack its founder's lifestyle.
What’s Next
With the trial date set for April 27, the tech industry is bracing for what is expected to be one of the most consequential legal battles in the history of Silicon Valley. Attorneys for Microsoft, though not a direct defendant in the fraud claim, have already stated there is no evidence the tech giant "aided and abetted" any alleged fraud by OpenAI.
As the discovery phase concludes without the ketamine probe, both Altman and Musk are expected to testify. The jury will ultimately decide if OpenAI’s path from a humble research lab to a global AI hegemon was a natural evolution or a calculated deception.